This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page  |  Contact Us  |  Report Abuse  |  Sign In  |  Register
News & Press: Clinical News

Emerging therapeutic agents to lower lipoprotein(a) levels

Tuesday, November 12, 2013   (1 Comments)
Posted by: Sandra Tremulis
Share |

Emerging therapeutic agents to lower lipoprotein (a) levels.
Kolski B, Tsimikas S.

Curr Opin Lipidol. 2012 Dec;23(6):560-8. doi: 10.1097/MOL.0b013e3283598d81.

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California 92093-0682, USA.


Recent epidemiological and genetic studies have suggested that lipoprotein (a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD). There is now interest in evaluating Lp(a) as a therapeutic target. This review will summarize emerging therapeutic agents to lower Lp(a).RECENT FINDINGS:

Apheresis is the most efficacious method to lower Lp(a). Currently, there are no approved drugs to specifically lower Lp(a). However, recent data has demonstrated that Lp(a) can be significantly lowered, along with reductions in other apolipoprotein B-100 (apoB) containing lipoproteins, with antisense oligonucleotides to apoB, monoclonal antibodies to proprotein convertase subtilisin/kexin type 9, cholesterol ester transfer protein inhibitors, and thyromimetics. The farnesoid X receptor/fibroblast growth factor axis and interleukin-6 also influence Lp(a) levels and may be targets of therapy. Finally, specific apolipoprotein (a) [apo(a)] inhibitors apo(a) have been developed and reduce apo(a) mRNA and protein levels up to 86% without significantly affecting other lipoproteins.SUMMARY:

Lp(a) remains the last major lipoprotein disorder without any specific therapy. With the strong and accumulating data on its role as a causal risk factor for CVD, a rationale exists to develop novel agents to reduce Lp(a) and test the hypothesis that this will lead to reduced CVD events.


Arthur Aguirre says...
Posted Monday, January 20, 2014
This is promising! It's good to know people are working to develop treatments! Any idea when these might become available??

Community Search
Sign In
Login with LinkedIn

Latest News
809 Laurel Street #460
San Carlos, CA 94070